{"title":"Dubious $56,000 Alzheimerâ€™s drug spurs largest Medicare price hike ever","link":"https://arstechnica.com/?p=1813120","date":1637000456000,"content":"<div>\n<figure>\n  <img src=\"https://cdn.arstechnica.net/wp-content/uploads/2021/06/GettyImages-1233323560-800x533.jpeg\" />\n      <p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2021/06/GettyImages-1233323560.jpeg\">Enlarge</a> <span>/</span> Biogen Inc. headquarters in Cambridge, Massachusetts. Biogen Inc. shares soared after its controversial Alzheimer's disease therapy was approved by US regulators. (credit: <a href=\"https://www.gettyimages.com/detail/news-photo/pedestrians-walk-past-biogen-inc-headquarters-in-cambridge-news-photo/1233323560?adppopup=true\">Getty | Bloomberg</a>)</p>  </figure>\n\n\n\n\n\n\n<div><a name=\"page-1\"></a></div>\n<p>Seniors throughout the US will see a hefty increase to their health care premiums next year thanks in large part to Biogen's Alzheimer's drug, Aduhelm, which is priced at $56,000 per year and is not proven to be clearly effective at treating Alzheimer's.</p>\n<p>The Centers for Medicare &amp; Medicaid Services (CMS) <a href=\"https://www.cms.gov/newsroom/press-releases/cms-announces-2022-medicare-part-b-premiums\">announced Friday</a> that the standard monthly premium for Medicare Part B will rise from $148.50 in 2021 to $170.10 in 2022, an increase of $21.60 or roughly 14.5 percent. It is the largest increase ever in terms of dollars and among the largest percentage increases in recent years.</p>\n<p>CMS officials said Friday that Aduhelm was responsible for about half of the rise in Part B premiums, <a href=\"https://apnews.com/article/medicare-health-care-costs-medication-alzheimers-disease-health-27a6250da20a6ba6af4820525c64afc4\">according to the Associated Press</a>. Though the CMS is still determining how it will cover Aduhelm under Part B, the agency said the prospect of paying for Aduhelm at all required \"additional contingency reserves.\"</p></div><p><a href=\"https://arstechnica.com/?p=1813120#p3\">Read 9 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1813120&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"1a2e62d9879db35bae0c36acc34956669f00e22d4835611f1f734361f5eb654c","category":"Tech"}